Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259860 | 0.93 | CYP2A6 (0.35) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23303231 | 0.76 | GAA (0.47) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19038906 | 0.74 | MEN1 (0.36) | — | |
| SCHEMBL30536506 | 0.74 | MEN1 (0.36) | — | |
| SCHEMBL10803170 | 0.68 | CYP2A6 (0.37) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2149910 | 0.67 | CYP2A6 (0.54) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6952322 | 0.66 | CYP2A6 (0.41) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11576122 | 0.66 | CYP3A4 (0.46) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6947277 | 0.66 | CYP2A6 (0.41) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18527288 | 0.66 | CYP2A6 (0.41) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877949-B2 | Furo[3,2-g]chromene compounds and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-11-04 | — | — | US | disclosed |
| US-20130096112-A1 | FURO[3,2-G]CHROMENE COMPOUNDS AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096112-A1 | FURO[3,2-G]CHROMENE COMPOUNDS AND USES THEREOF | ESR2, ESR1, GPER1 | CYP2A6 163/4885KDM4E 3229/4885CYP3A4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.